IP Library Granted Patent US 11,267,797
Granted Patent B2
US 11,267,797 · App. 16/907,463 · Granted Mar 8, 2022

Anticancer agent

Inventors: Yoshinobu Yoshimura (Kyoto, JP); Masayasu Kasai (Kyoto, JP); Yoshimichi Shoji (Kyoto, JP); Shigemitsu Takeda (Kyoto, JP)
Assignees: Kyoto Pharmaceutical Industries, Ltd.; Sumitomo Dainippon Pharma Co., Ltd.
C07D307/92A61P35/00C07D405/12C07D407/12C07F9/65517C07H7/06C07H15/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,267,797
App. No.
16/907,463
Granted
Mar 8, 2022
Kind
B2
Abstract

The problem of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention relates to a compound represented by the formula (IA): [wherein each symbol is as described in the DESCRIPTION] or a pharmaceutically acceptable salt thereof.

Claims (120)

1. A production method of a compound represented by the formula (Ia):

or a pharmaceutically acceptable salt thereof,

wherein

each R 1 is independently

hydrogen

halogen

hydroxy,

amino,

cyano,

nitro,

C 1-12 alkyl,

C 2-6 alkenyl,

C 2-6 alkynyl,

C 3-7 cycloalkyl,

C 3-7 cycloalkenyl,

aryl,

heterocyclyl group,

C 1-6 alkoxy,

aryloxy,

C 1-6 alkylthio, or

arylthio, or

two R 1 bonded to the adjacent carbon atoms on a benzene ring are optionally joined to form C 1-4 alkylenedioxy,

R 2 is

C 1-12 alkyl optionally substituted by substituent(s) selected from substituent group α,

C 2-6 alkenyl optionally substituted by substituent(s) selected from substituent group α,

C 2-6 alkynyl optionally substituted by substituent(s) selected from substituent group α,

C 3-7 cycloalkyl optionally substituted by substituent(s) selected from substituent group α,

aryl optionally substituted by substituent(s) selected from substituent group α,

aryl C 1-6 alkyl optionally substituted by substituent(s) selected from substituent group α, or

heterocyclyl optionally substituted by substituent(s) selected from substituent group α,

n is an integer of 1-4 when R 1 is hydrogen,

n is an integer of 1 or 2 when R 1 is not hydrogen, and

the substituent group a consists of

halogen,

hydroxy,

optionally substituted amino,

carboxy,

C 1-6 alkoxycarbonyl,

sulfo group,

phosphoric acid group,

di C 1-6 alkyl phosphoric acid group,

cyano,

optionally substituted C 1-6 alkyl,

C 3-7 cycloalkyl,

C 3-7 cycloalkyl C 1-6 alkyl,

optionally substituted C 1-6 alkoxy,

C 1-6 alkylthio,

optionally substituted aryl,

optionally substituted aryloxy,

aryl C 1-6 alkoxy,

optionally substituted heterocyclyl,

optionally substituted C 1-6 alkylcarbonyl,

heterocyclylcarbonyl,

optionally substituted C 1-6 alkylcarbonyloxy,

optionally substituted C 3-7 cycloalkylcarbonyloxy,

arylcarbonyloxy,

monocyclic heterocyclylcarbonyloxy,

optionally substituted C 1-6 alkoxycarbonyloxy,

optionally substituted heterocyclyl C 1-6 alkoxycarbonyloxy,

C 3-7 cycloalkyloxycarbonyloxy,

heterocyclyloxycarbonyloxy,

optionally substituted heterocyclyloxy,

tri C 1-6 alkylammonio,

optionally substituted C 1-6 alkylsulfonyl, and

C 1-6 alkylsulfamoylcarbonyl, comprising

a step of reacting a compound represented by the formula (10):

or a salt thereof, wherein R 1 and n are as defined for R 1 and n in said formula (Ia), in inert solvent, and a compound represented by the formula (11):

R 2 —OH   (11)

or a salt thereof, wherein R 2 is as defined for R 2 in said formula (Ia).

2. The production method according to claim 1 , further comprising a step of producing a compound represented by the formula (10):

or a salt thereof, wherein R 1 and n are as defined above, by reacting a compound represented by the formula (2):

or a salt thereof, wherein R′, X, and n are as defined above,

in inert solvent in the presence of a base and a compound represented by the formula (9):

before the step of reacting a compound represented by the formula (10) or a salt thereof.

3. The production method according to claim 2 , wherein the base comprises N,N-dimethylaminopyridine.

4. The production method according to claim 2 , further comprising a step of producing a compound represented by the formula (2):

or a salt thereof, wherein R 1 , X, and n are as defined above, from a compound represented by the formula (1):

or a salt thereof, wherein R 1 and n are as defined above, before the step of reacting a compound represented by the formula (2) or a salt thereof.

5. The production method according to claim 1 , wherein R 1 is hydrogen or halogen.

6. The production method according to claim 1 , wherein the substituent group α consists of

halogen,

hydroxy,

optionally substituted amino,

carboxy,

C 1-6 alkoxycarbonyl,

sulfo group,

phosphoric acid group,

di C 1-6 alkyl phosphoric acid group,

cyano,

C 1-6 alkyl,

C 3-7 cycloalkyl,

C 1-6 alkoxy,

optionally substituted aryl,

optionally substituted aryloxy,

aryl C 1-6 alkoxy,

optionally substituted heterocyclyl group,

optionally substituted C 1-6 alkylcarbonyl,

heterocyclylcarbonyl,

optionally substituted C 1-6 alkylcarbonyloxy,

optionally substituted C 3-7 cycloalkylcarbonyloxy,

monocyclic heterocyclylcarbonyloxy,

optionally substituted C 1-6 alkoxycarbonyloxy,

optionally substituted heterocyclyl C 1-6 alkoxycarbonyloxy,

C 3-7 cycloalkyloxycarbonyloxy,

heterocyclyloxycarbonyloxy,

optionally substituted heterocyclyloxy, and

tri C 1-6 alkylammonio.

7. The production method according to claim 1 , wherein

R 2 is C 1-6 alkyl optionally substituted by substituent(s) selected from substituent group α, C 2-6 alkenyl optionally substituted by substituent(s) selected from substituent group α, C 3-7 cycloalkyl optionally substituted by substituent(s) selected from substituent group α, aryl optionally substituted by substituent(s) selected from substituent group α, aryl C 1-6 alkyl optionally substituted by substituent(s) selected from substituent group α, or heterocyclyl optionally substituted by substituent(s) selected from substituent group α, and

the substituent group a consists of halogen, hydroxy, optionally substituted amino, carboxy, sulfo group, phosphoric acid group, cyano, C 1-6 alkyl, C 3-7 cycloalkyl, C 1-6 alkoxy, aryl, and heterocyclyl group.

8. The production method according to claim 1 , wherein R 2 is

(1) C 1-6 alkyl optionally substituted by substituent(s) selected from hydroxy, optionally substituted amino, carboxy, sulfo group, phosphoric acid group, di C 1-6 alkyl phosphoric acid group, heterocyclyl, optionally substituted C 1-6 alkoxy, optionally substituted C 1-6 alkylcarbonyloxy, monocyclic heterocyclylcarbonyloxy, C 3-7 cycloalkyloxycarbonyloxy, and heterocyclyloxycarbonyloxy,

(2) C 2-6 alkynyl optionally substituted by substituent(s) selected from hydroxy, optionally substituted amino, carboxy, sulfo group, phosphoric acid group, and heterocyclyl,

(3) heterocyclyl group optionally substituted by substituent(s) selected from hydroxy and optionally substituted C 1-6 alkyl, or

(4) aryl C 1-6 alkyl substituted by substituent(s) selected from hydroxy, optionally substituted amino, carboxy, sulfo group, phosphoric acid group, and heterocyclyl.

9. The production method according to claim 1 , wherein R 2 is

(1) C 1-6 alkyl optionally substituted by substituent(s) selected from hydroxy, optionally substituted C 1-6 alkoxy, optionally substituted C 1-6 alkylcarbonyloxy, and monocyclic heterocyclylcarbonyloxy, or

(2) C 2-6 alkynyl optionally substituted by substituent(s) selected from optionally substituted amino and heterocyclyl, or

(3) heterocyclyl optionally substituted by optionally substituted C 1-6 alkyl.

10. The production method according to claim 1 , wherein R 1 is hydrogen.

Assignments (1)
NAME AND ADDRESS CHANGE Recorded May 4, 2022
From: SUMITOMO DAINIPPON PHARMA CO., LTD.
To: SUMITOMO PHARMA CO., LTD.
Reel/Frame 059855/0333 →
Priority Claims (2)
JP JP2014-119113 · Jun 9, 2014 · national
JP JP2015-021492 · Feb 5, 2015 · national
Continuity (4)
Continuation 16455707 · Jun 27, 2019
Continuation 15987525 · May 23, 2018
Continuation 15317471
Related Publication 20200317630A1 · Oct 8, 2020